Applications
News & Events
Contact

The EuLV™ system, a stable lentiviral vector production system, employs inducible suspension-based producer cell lines in the high cell-density, serum-free media to produce lentiviral vectors.

The EuLV™ stable system emerges as the ideal option for large-scale LVV manufacturing because of:

  • Streamlined vector production:  No addition of raw materials such as DNA plasmids and transfection reagents.
  • Scalable vector production:  the serum-free suspension cell culture process is easier to scale up.
  • Higher titer yield and simpler process development.
  • Reproducible vector production:  To produce safer viral vectors with low batch-to-batch variability.

EuLV™ Stable LVV System Superior to Transient Transfection System

Advantages

-50 %

A 50% Reduction in Production Procedure

-80 %

An 80% Reduction in Production Costs

100 Fold

A 100-Fold Increase in Production Efficiency

EuLV™ Stable LVV System Superior to Transient Transfection System


EuBioX - Fully Automated Cell Screening System

The EuBioX, an in-house developed fully automated cell screening system, plays an instrumental role in the EuLV™ stable producer cell line development. The EuBioX system not only streamlines the process of the single clone selection, allowing to quickly and accurately verify the desired single clones but also significantly reduces the screening workload while enhancing the accuracy of the lentiviral producer cell line screening process.

EuLV™ Producer Cell Line Development Process

EuLV™ Producer Cell Line Development Process

EurekaBio provides comprehensive CRO services for the EuLV™ lentiviral vector stable producer cell line development.

By simply providing gene sequences or plasmids, customers can expect to receive the GOI-specific monoclonal producer cell lines within a timeframe of 5 months. Additionally, EurekaBio offers a variety of add-on services such as GOI optimization, clone identification and stability studies, and upstream and downstream process development, allowing for a tailored and comprehensive solution. 

The EuLV™ Stable System The path to reliable and scalable lentiviral vectors production

An efficient and scalable lentiviral vector (LVV) manufacturing solution is needed to address the constant growth in the number of clinical trials in the cell and gene therapy space. Upstream production of LVV requires a consistent and high-titer scalable production system, whilst downstream production faces its own optimization challenges to obtain a high yield and high purity product.

EurekaBio has developed its proprietary EuLV™ system which can deliver stable producer cell lines in as short as 5 months. The EuLV™ system has irreplaceable advantages in terms of process reliability, scale-up capability, production cost, and virus product safety.

High-yield

Generates stable clones with high titers up to 5.4E11 TU/L (10~100 higher than Transient Titer).

Cost-effective

Eliminates total plasmids manufacturing cost.

Scalable

Produces large amounts of LVV in the serum-free suspension HEK293T system.

Reproducible

Eliminates variable transient transfection processes

Fast

Delivers research cell bank (RCB) in as fast as 5 months

Plug-and-Go

GMP-compliant stable cell line, free of operation

Applications

Download Product Brochure

Related Products